Results 211 to 220 of about 39,794 (275)
Current practice of cardiac resynchronization therapy (CRT) in the real world: insights from the European CRT survey [PDF]
, 2009 Hürlimann, D, Steffel, J
core +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 2023-2033, June 2025.Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami +11 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 2077-2086, June 2025.Abstract Aims The inflammatory profile of cardiogenic shock (CS) after myocardial infarction affects outcomes; however, little is known about the impact of inflammatory changes in CS caused by acute decompensated heart failure (ADHF‐CS). We measured levels of inflammatory cytokines in patients with ADHF‐CS admitted to a cardiac intensive care unit ...
Darshan H. Brahmbhatt +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 2347-2352, June 2025.
Daigo Nishijo +19 more
wiley +1 more source
Temporal profiling of M‐TEER‐related complications
ESC Heart Failure, Volume 12, Issue 3, Page 2107-2112, June 2025.Abstract Aims Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) is known for its low complication rates. However, the optimal level and duration of post‐procedural care remain unclear. This study aimed to identify the specific timeframe of post‐procedural complications following M‐TEER.
Jafer Haschemi +8 more
wiley +1 more source
Tissue characterization using cardiac magnetic resonance imaging and response to cardiac resynchronization therapy. [PDF]
EuropaceKim SE +12 more
europepmc +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 2125-2133, June 2025.Abstract Background Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent one of the four pillars of heart failure (HF) pharmacological therapy. Objective The study aims to clarify SGLT2i antiarrhythmic effect on patients with HF with reduced ejection fraction (HFrEF) in terms of atrial and ventricular arrhythmias (AAs and VAs) reduction ...
Marco Valerio Mariani +17 more
wiley +1 more source
Conduction System Pacing-Optimized Cardiac Resynchronization Therapy for Congenitally Corrected Transposition. [PDF]
JACC Case RepSu J, Lam WW, Contractor A, Moore JP.
europepmc +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 1620-1629, June 2025.Abstract Aims Patients hospitalized with acute heart failure (AHF) treated with a 7 day prednisone course in the CORTAHF pilot trial had a greater improvement in health‐related quality of life (QoL) at Day 7 in both the overall population and in patients with baseline interleukin 6 > 13 pg/mL.
Matteo Pagnesi +21 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 2190-2199, June 2025.In this retrospective, observational study of a real‐life cohort of patients with heart failure with reduced ejection fraction, long‐term survival was improved in patients who achieved sustained reverse remodeling. Greater increases in ejection fraction (EF) and reductions in left ventricular end‐systolic diameter at the time of EF recovery, greater ...
Silas Ramos Furquim +13 more
wiley +1 more source